Chinese clinical oncology最新文献

{"title":"Eribulin and trastuzumab in early-line HER2-positive metastatic breast cancer: evaluating an active chemotherapy partner in an evolving treatment landscape.","authors":"Hannah L Chang, Irene M Kang, Hope S Rugo","doi":"10.21037/cco-2025-aw-162","DOIUrl":"https://doi.org/10.21037/cco-2025-aw-162","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"26"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short- and long-term outcomes after laparoscopic versus open total gastrectomy for stage 0-I gastric cancer: a multicenter, retrospective analysis.","authors":"Fangyao Zhou, Zaisheng Ye, Chengbin Zheng, Zhaojun Zhang, Wenjun Xiong, Junjiang Wang, Weixian Hu, Jiabin Zheng, Bin Luo, Wei Wang, Yong Li, Luchuan Chen, Xingyu Feng","doi":"10.21037/cco-2025-aw-152","DOIUrl":"https://doi.org/10.21037/cco-2025-aw-152","url":null,"abstract":"<p><strong>Background: </strong>Laparoscopic surgery has been increasingly adopted in the treatment of gastric cancer. Although the safety and efficacy of laparoscopic distal gastrectomy have been well established, evidence regarding laparoscopic total gastrectomy (LTG) remains limited, especially for early-stage disease. This study aimed to compare the short-term surgical outcomes and long-term survival between LTG and open total gastrectomy (OTG) in patients with stage 0-I gastric cancer.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinicopathological data of 122 patients with stage 0-I gastric cancer underwent radical LTG or OTG from January 2010 to December 2013. Multivariate regression with a generalized estimation equation (GEE) was used to analyze the differences in total complications, LTG-related complications and OTG-related complications between the laparoscopic and open groups. The inverse probability of treatment weighting (IPTW) Kaplan-Meier survival curve was used to compare the long-term survival of the two groups. The primary outcome was the short-term outcomes and long-term survival of LTG with traditional OTG for stage 0-I gastric cancer.</p><p><strong>Results: </strong>The incidence of postoperative complications was 16.4% in the LTG group and 18.4% in the OTG group, with no statistically significant difference between the two groups (P>0.05). In the adjusted multivariate GEE regression for OTG-related complications, the risk of OTG-related complications in the laparoscopic group was 0.111 (95% confidence interval: 0.016-0.771, P=0.03). Before and after IPTW adjustment, there was no statistically significant difference in survival between the LTG group and the OTG group (P=0.28 and P=0.34).</p><p><strong>Conclusions: </strong>LTG is safe and feasible to apply in stage 0-I gastric cancer. Comparing OTG, LTG with a similar overall complication rate and long-term survival, but reduce the incidence of OTG-related complications and does not increase the risk of LTG-related complications in stage 0-I gastric cancer. However, these findings still need to be confirmed in a large clinical trial.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TP63 drives TKI resistance in EGFR-mutant lung cancer via ferroptosis inhibition.","authors":"Kehan Li, Jiane Liu, Wenjuan Wang, Guangmin Zhang, Lina Zhu, Linlin Liu, Xiaohui Xu","doi":"10.21037/cco-2025-aw-151","DOIUrl":"https://doi.org/10.21037/cco-2025-aw-151","url":null,"abstract":"<p><strong>Background: </strong>The emergence of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) presents a significant obstacle in the therapeutic strategy for EGFR-mutant non-small cell lung cancer (NSCLC). While secondary mutations explain some cases, adaptive resistance mechanisms involving lineage plasticity and metabolic rewiring are increasingly recognized but poorly understood. This study aimed to investigate the role of the transcription factor TP63 in mediating adaptive resistance to EGFR-TKIs, with a focus on its potential regulation of ferroptosis.</p><p><strong>Methods: </strong>To investigate these mechanisms, we generated osimertinib-resistant derivatives of EGFR-mutant PC9 and HCC827 cell lines. We utilized short hairpin RNA (shRNA) interference to silence TP63 and performed functional assays including cell viability, colony formation, wound-healing, and transwell invasion assays. Mechanistic insights were gained through integrated RNA sequencing (RNA-seq), immunofluorescence, and lipid peroxidation assays using BODIPY 581/591 C11.</p><p><strong>Results: </strong>We identified the transcription factor TP63 as a master regulator of adaptive resistance, showing marked upregulation in resistant cells. Although TP63 depletion did not affect basal cell viability, its loss significantly restored sensitivity to osimertinib, suppressing proliferation, clonogenic growth, and invasive potential. Transcriptomic and biochemical analyses revealed that TP63 maintains redox homeostasis by transcriptionally activating GPX4 and antioxidant gene networks. Consequently, TP63 silencing collapsed this defense system, leading to the accumulation of lipid peroxides and inducing ferroptotic cell death under drug pressure.</p><p><strong>Conclusions: </strong>Clinically, high TP63 expression correlates with reduced overall survival in EGFR-mutant NSCLC patients. These findings define a critical TP63-GPX4 ferroptosis axis that safeguards tumor cell survival during therapeutic stress, highlighting ferroptosis induction as a potential therapeutic strategy to overcome EGFR-TKI resistance.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolution of bispecific antibodies in multiple myeloma.","authors":"Rebecca Ibrahim, Nadine Khalife, Ahmadreza Arbab, Annoir Shayya, Cendrella Bou Orm, Rita Khoury, Cynthia Khalil, Nohad Masri, Zamzam Tikriti, Elissar Moujaes, Mohamad Ali Hachem, Joud Sawan, Claude Chahine, Khalil Saleh","doi":"10.21037/cco-25-110","DOIUrl":"10.21037/cco-25-110","url":null,"abstract":"<p><p>The treatment of multiple myeloma (MM) has revolutionized over the last decade with the advent of CD38-targeting monoclonal antibodies such as daratumumab and isatuximab that were integrated into the therapeutic arsenal of patients with newly diagnosed or with relapsed and/or refractory (R/R) MM. Moreover, the advent of B-cell maturation antigen (BCMA)-targeting therapy continue to improve outcomes in patients with R/R disease. Multiple classes of these agents have been developed such as chimeric antigen receptor (CAR)-T cell therapy and antibody-drug conjugates. Another class of antigen-target therapy was the bispecific antibodies (BsAbs). The class, targeting CD20 and CD3, is now commonly used in patients with R/R B-cell lymphoma. It has also been developed for the treatment of patients with MM with other target antigens such BCMA, G protein-coupled receptor family C group 5 member D (GPRC5D), or Fc receptor-homolog 5 (FcRH5). Four BsAbs-teclistamab, elranatamab, linvoseltamab, and talquetamab-are currently approved by the Food and Drug Administration (FDA) for the management of patients with R/R MM. We review in this paper the most studied BiAbs, their mechanism of action, clinical activity, the mechanism of resistance. We discuss the place of BiAbs in the therapeutic arsenal of MM and the emergence of novel strategies such as combining two classes of BiAbs (for example teclistamab and talquetamab) or novel therapies such as trispecific antibodies to overcome resistance and increase the efficacy of BiAbs.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"12"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a diagnostic model based on artificial intelligence for diagnosing pancreatic cancer.","authors":"Fedor N Paramzin, Victor V Kakotkin, Dmitry A Burkin, Zakhar A Ponimash, Mikhail A Nikitin, Mikhail A Agapov","doi":"10.21037/cco-25-17","DOIUrl":"10.21037/cco-25-17","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The global incidence and mortality rates of pancreatic cancer have been on the rise in recent decades. At the same time, pancreatic cancer occupies a leading position among malignant neoplasms, which are often first detected at advanced stages, which significantly worsens the prognosis for patients. In this regard, it is important to create automated systems capable of accurately segmenting and diagnosing pancreatic tumors at an early stage. A diagnostic model based on U-Net is proposed and evaluated, aimed at improving the accuracy of automatic segmentation of medical images for segmentation of the pancreas and identification of malignant changes in computed tomography (CT) images.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The diagnostic model of the algorithm was based on the U-Net architecture, and image texture indices were used as control features. The neural network algorithm was trained using CT data from 310 patients with pancreatic neoplasms. Segmentation datasets from 280 pancreatic cancer studies from an open source, Memorial Sloan Kettering Cancer Center, was used to segment medical images and train the algorithm. Manual segmentation of medical images obtained at Regional Clinical Hospital of the Kaliningrad was performed using specialized three-dimensional (3D) Slicer software: CT images of 30 patients with pancreatic neoplasms. Diagnoses in the patient group were confirmed by morphological diagnostics, including examination of biopsy samples and/or surgical material. Four types of indicators were used to quantify segmentation results: Dice similarity coefficient (DSC), accuracy, sensitivity, and specificity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The diagnostic model achieved an accuracy of 88% in the classification of pancreatic cancer, and the DSC segmentation accuracy factor was 70%, demonstrating sensitivity of 98% and specificity of 98%. The results obtained emphasize the effectiveness of CT image analysis for the diagnosis of pancreatic malignancies using a neural network algorithm that uses textural features of medical images. In the course of the work, a number of limitations were identified: obtaining false positive results during segmentation, a limited number of medical images and clinical data that may affect the representativeness of the developed diagnostic model. Nevertheless, the results show the prospects for integrating artificial intelligence (AI) technologies into clinical practice, which can significantly improve diagnostic efficiency.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The use of neural network algorithms based on the textural features of medical images has significant potential in the field of clinical decision support systems. Despite certain limitations in the course of work, the using textural features for training neural networks will increase the accuracy of diagnosis of pancreatic malignancies and will play an important role in determining patient management strategies and monitoring the ","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"3"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the clinical features and surgical treatment of small intestinal stromal tumor: a retrospective study based on 119 cases.","authors":"Linxiang Xu, Congxian Yang, Jing Liu, Guangjin Guo, Longfang Quan, Huilian Qiao, Guoli Gu, Zhiwei Dong","doi":"10.21037/cco-25-84","DOIUrl":"10.21037/cco-25-84","url":null,"abstract":"<p><strong>Background: </strong>Small intestinal stromal tumors (SISTs) are mesenchymal neoplasms originating from the interstitial cells of Cajal in the small intestine. As a distinct subtype of gastrointestinal stromal tumors (GISTs), SISTs exhibit greater aggressiveness and poorer prognosis compared to gastric GISTs. Due to their anatomically ambiguous location and nonspecific symptoms, early diagnosis remains challenging. This study conducts a retrospective analysis of clinical data to systematically summarize their clinical characteristics and management experience, aiming to provide insights for addressing diagnostic challenges.</p><p><strong>Methods: </strong>Clinical data from 119 patients with primary SIST who underwent surgical treatment at the Air Force Medical Center between November 2013 and March 2025 were retrospectively analyzed.</p><p><strong>Results: </strong>The clinical presentation of SIST was often insidious, with intermittent gastrointestinal bleeding (melena or hematochezia) observed as the initial symptom in 84.9% of patients. Anemia was frequently observed during the disease course. Caution is warranted to avoid misdiagnosis as superficial gastritis. The tumors predominantly occurred in the jejunum and ileum. A significant correlation was identified between the risk of recurrence and Ki-67 expression levels. Through a precision medicine approach encompassing \"symptom and sign evaluation, radiographic assessment, intraoperative dynamic decision-making, and surgical resection\", a stratified surgical strategy was implemented. This approach prioritized both complete tumor eradication and minimal invasiveness.</p><p><strong>Conclusions: </strong>The diagnosis and management of SIST require vigilance regarding overlapping symptoms and anatomical obscurity, emphasizing the integration of multimodal imaging and a minimally invasive-prioritized surgical strategy.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"2"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protocol for the impact of medication therapy management on efficacy and safety of postoperative anticoagulation therapy in patients with colorectal cancer: an open-label, prospective and randomized clinical trial.","authors":"Jieling Mao, Zhikun Liang, Min Gao, Xiaoyan Huang, Jingwen Xie, Chunmei Dai, Jianfu Zhao, Yongjuan Ding, Genshen Ye, Yaobo Wang, Li Qin, Xiaoyan Li","doi":"10.21037/cco-25-111","DOIUrl":"10.21037/cco-25-111","url":null,"abstract":"<p><strong>Background: </strong>Anticoagulants, classified as high-risk medications, are commonly used and are associated with significant potential harm in postoperative patients. Patients with colorectal cancer (CRC) are among the most susceptible populations. Single-component pharmacist intervention has demonstrated conflicting efficacy in improving anticoagulant safety. Meanwhile, it remains unclear whether comprehensive medication therapy management (MTM), which integrates medication review, personalized education, and long-term follow-up, can effectively reduce adverse drug events (ADEs). This study aims to assess the impact of a comprehensive MTM pathway on anticoagulant-related ADEs in this high-risk population.</p><p><strong>Methods: </strong>This study will be a prospective, multicenter, open-label, randomized, parallel-group trial designed to assess the impact of the MTM pathway on anticoagulant efficacy and safety in patients diagnosed with CRC, admitted for elective radical surgery, and developing acute venous thromboembolism (VTE) that requires long-term anticoagulant therapy in comparison with the current clinical standard of care. In total, 327 patients will be enrolled with randomization at a 1:1 ratio into intervention and control groups. Patients in the intervention group will receive MTM interventions at three key time points: during hospitalization, at discharge, and post-discharge. A total of 9 times of MTM services will be provided to patients within 6 months after discharge. The primary outcome is anticoagulant-related clinically important medication errors (CIME), including preventable or ameliorable ADEs and potential ADEs. The secondary outcomes are (I) preventable or ameliorable ADEs; (II) potential ADEs due to discrepancies or non-adherence; and (III) preventable or ameliorable ADEs judged to be serious, life-threatening, or fatal. Intention-to-treat (ITT) analysis will serve as the primary analytical approach.</p><p><strong>Discussion: </strong>This study will provide evidence on whether the MTM pathway improves the efficacy and safety of anticoagulant therapy in patients with CRC who develop postoperative VTE.</p><p><strong>Trial registration: </strong>NCT06998745 (date of registration: 2025-5-10) (Protocol version: 2024-7-16, Version 2.0).</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"6"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in percutaneous lung ablation: techniques, outcomes, and future directions-a literature review.","authors":"Adam G Fish, David C Madoff","doi":"10.21037/cco-25-114","DOIUrl":"10.21037/cco-25-114","url":null,"abstract":"<p><strong>Background and objective: </strong>Percutaneous thermal ablation has become an important local treatment option for patients with primary or metastatic lung tumors who are not optimal surgical candidates. Radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation (CA) are increasingly used in selected patients, with expanding evidence supporting their safety and effectiveness. This review summarizes current techniques, patient selection considerations, clinical outcomes, and future directions in percutaneous lung tumor ablation.</p><p><strong>Methods: </strong>A narrative review of the literature was performed using PubMed, MEDLINE, major radiology and oncology journals, and reference lists from key manuscripts. Searches focused on percutaneous thermal ablation modalities, outcomes, complications, and emerging technologies in lung tumor management. Representative studies were selected to illustrate current evidence and practice patterns.</p><p><strong>Key content and findings: </strong>Patient selection for lung ablation depends on tumor size, number, location, and pulmonary reserve. MWA provides more predictable heating zones and is less affected by heat-sink effects, while RFA is more limited in this setting. CA allows controlled ablation margins and preservation of adjacent lung parenchyma, with favorable tolerance near critical structures. Across modalities, percutaneous ablation achieves meaningful local control and survival in early-stage non-small cell lung cancer (NSCLC) and oligometastatic disease. Long-term survival after MWA for stage IA NSCLC can approach surgical outcomes in well-selected patients, though disease-free survival remains higher with resection. Compared with stereotactic body radiotherapy (SBRT), ablation generally yields lower local control but similar overall survival (OS) in some cohorts. Complications such as pneumothorax, pleural effusion, and hemorrhage are usually manageable, with CA often associated with fewer major adverse events. Emerging innovations, including bronchoscopic ablation systems, non-thermal energy platforms, and artificial intelligence (AI)-assisted planning, may enhance precision and broaden indications.</p><p><strong>Conclusions: </strong>Percutaneous lung ablation is a safe and effective local therapy for selected patients with primary or metastatic lung tumors, particularly those with limited pulmonary reserve or requiring repeat local treatment. Ongoing advances in technology and patient selection strategies are likely to strengthen its role within multidisciplinary lung cancer management.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"10"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal relationship between renin-angiotensin system inhibitors and cancer: a two-sample, two-step Mendelian randomization study.","authors":"Chenggong Zeng, Juanhua Zhu, Xi Zhen, Yan Mao, Zhiqing Wei, Zijun Zhen","doi":"10.21037/cco-2025-aw-131","DOIUrl":"10.21037/cco-2025-aw-131","url":null,"abstract":"<p><strong>Background: </strong>The renin-angiotensin system (RAS), particularly the angiotensin II (AT2)/angiotensin I receptor axis, is implicated in promoting tumorigenesis. However, the causal relationship between angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) use and cancer remains controversial. This study employed a two-sample, two-step Mendelian randomization (MR) approach to investigate whether there is a causal relationship between ACEI/ARB use and various cancers, and if so, the direction and potential mechanism of this association.</p><p><strong>Methods: </strong>Genome-wide association study (GWAS) summary statistics for ACEI/ARB use, 24 site-specific cancers, and potential mediators were obtained from the GWAS Catalog, Integrative Epidemiology Unit (IEU) OpenGWAS project, and FinnGen study. Potential causal effect were primarily estimated using the inverse variance weighted (IVW) method. Sensitivity analyses, including Cochran's Q test, MR-Egger regression, and leave-one-out analysis, were performed to assess the robustness of the findings.</p><p><strong>Results: </strong>MR analyses demonstrated causal protective effects of genetically proxied ACEI/ARB use on gastric [odds ratio (OR) =0.834, P<0.001], colorectal (OR =0.900, P=0.006), lung (OR =0.928, P=0.02), breast (OR =0.942, P=0.03), and endometrial cancer (OR =0.900, P=0.006). These causal associations remained consistent in validation and sensitivity analyses. Mediation analyses indicated the causal, protective effects were partially mediated by vascular endothelial growth factor A (VEGF-A), total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C).</p><p><strong>Conclusions: </strong>This MR study provides robust genetic evidence supporting a causal protective role of ACEI/ARB use in reducing the risk of gastric, colorectal, lung, breast, and endometrial cancers, which is partially mediated by VEGF-A, total cholesterol, triglycerides, LDL-C, and HDL-C.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"4"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cadonilimab plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a step forward for bispecific immunotherapy?","authors":"Jia Li Low, Lu Lu Huang, Boon Cher Goh","doi":"10.21037/cco-2025-aw-130","DOIUrl":"https://doi.org/10.21037/cco-2025-aw-130","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 1","pages":"19"},"PeriodicalIF":2.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}